Red Crane Wealth Management LLC Purchases New Shares in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Red Crane Wealth Management LLC acquired a new position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 340,236 shares of the company’s stock, valued at approximately $171,000. Red Crane Wealth Management LLC owned 0.15% of Lineage Cell Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently modified their holdings of LCTX. SG Americas Securities LLC purchased a new stake in shares of Lineage Cell Therapeutics during the third quarter worth about $46,000. GSA Capital Partners LLP purchased a new position in shares of Lineage Cell Therapeutics in the third quarter valued at approximately $84,000. MAI Capital Management boosted its stake in shares of Lineage Cell Therapeutics by 2.2% in the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock worth $1,516,000 after acquiring an additional 35,907 shares during the last quarter. Raffles Associates LP raised its stake in Lineage Cell Therapeutics by 3.4% in the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock valued at $4,081,000 after purchasing an additional 150,000 shares during the last quarter. Finally, State Street Corp lifted its holdings in Lineage Cell Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after purchasing an additional 45,483 shares in the last quarter. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on LCTX. D. Boral Capital lowered their target price on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, February 11th. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, February 11th. Finally, Maxim Group reduced their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, January 10th.

Lineage Cell Therapeutics Trading Down 3.2 %

Shares of NYSEAMERICAN LCTX opened at $0.64 on Wednesday. The stock has a market cap of $141.53 million, a price-to-earnings ratio of -5.35 and a beta of 1.21. Lineage Cell Therapeutics, Inc. has a 1-year low of $0.48 and a 1-year high of $1.61.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.